The report offers detailed coverage of Human Prothrombin Complex industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Human Prothrombin Complex by geography. The report splits the market size, by volume and value, on the basis of application type and geography.
Prothrombin complex concentrate (PCC), also known as factor IX complex, is a medication made up of blood clotting factors II, IX, and X. Some versions also contain factor VII. It is used to treat and prevent bleeding in hemophilia B if pure factor IX is not available.
The global average price of Human Prothrombin Complex is in the increasing trend, from 124 USD/Unit in 2013 to 137 USD/Unit in 2017. With the situation of global economy, prices will be in increasing trend in the following five years.
The classification of Human Prothrombin Complex includes 500 IU/Vial, 600 IU/Vial, 1000 IU/Vial and others, and the proportion of 500 IU/Vial in 2017 is about 51%.
Human Prothrombin Complex is widely used in Hemophilia B, Vitamin K Deficiency and other diseases. The most proportion of Human Prothrombin Complex is Hemophilia B, and the proportion of sales is 48%.
North America is the largest consumption place, with a consumption market share nearly 46% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 33%.
Market competition is not intense. Shire, CSL, Grifols, Octapharma, Hualan Biological, Meheco Xinxing Pharma, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
The report forecast global Human Prothrombin Complex market to grow to reach xxx Million USD in 2020 with a CAGR of xx% during the period 2021-2025.
First, this report covers the present status and the future prospects of the global Human Prothrombin Complex market for 2015-2025.
And in this report, we analyze global market from 5 geographies: Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East & Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru].
Key Companies
Shire
CSL
Grifols
Octapharma
Hualan Biological
Meheco Xinxing Pharma
At the same time, we classify Human Prothrombin Complex according to the type, application by geography. More importantly, the report includes major countries market based on the type and application.
Market Segment as follows:
Market by Order Type
500 IU/Vial
600 IU/Vial
1000 IU/Vial
Others
Market by Application
Hemophilia B
Vitamin K Deficiency
Others
By Region
Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia]
Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
North America[United States, Canada, Mexico]
Middle East & Africa[GCC, North Africa, South Africa]
South America[Brazil, Argentina, Columbia, Chile, Peru]
The research provides answers to the following key questions:
• What is the estimated growth rate and market share and size of the Human Prothrombin Complex market for the forecast period 2021 - 2025?
• What are the driving forces in the Human Prothrombin Complex market for the forecast period 2021 - 2025?
• Who are the prominent market players and how have they gained a competitive edge over other competitors?
• What are the market trends influencing the progress of the Human Prothrombin Complex industry worldwide?
• What are the major challenges and threats restricting the progress of the industry?
• What opportunities does the market hold for the prominent market players?